Ranked board
GLP-1 providers that say they treat men, and what a year at each really costs
Same rule as the women's board, run the other way: a company is here because its own pages say it treats men — two of them sell to men specifically, the rest publish programs for both sexes — and a company that says nothing about who it treats is on neither board. That makes this a genuinely different list from our main GLP-1 ranking rather than the same one under a different heading, which is what it was until each review carried the fact. Nothing here asserts a clinical difference between the sexes; it ranks what companies charge and reports what they say.
Disclosure: Some links on this site are affiliate or referral links. If you start a treatment or buy a product through them, we may earn a commission at no additional cost to you. Read our full disclosure.
What gets on this board
Every company with a published review here that sells a GLP-1 and whose own published words say it serves men — either by addressing men specifically, or by publishing programs for both sexes. Each appears once, on its cheapest GLP-1 over a year. A company whose own site says nothing about who it treats is on NEITHER this board nor the women's one: an absent record means the question has not been settled first-party, and it is not read as a yes. Companies we did establish an audience for and still left off are named below with the sentences that decided it.
What decides the order
Companies we have an affiliate relationship with are listed first, and we may earn a commission if you start with one. Within that group and within the rest, the order is true-year cost, cheapest first — the price of one cycle with no commitment, multiplied by the number of times a year it is actually billed. The prices themselves are read off each company's own page and are the same either way.
What the spread looks like
$1,188
Cheapest year
$6,936
Dearest year
$5,748
Between the two
Ranked by what a year actually costs
The advertised column is what the company leads with. The walk-away column is what one cycle costs if you stop after it. The year column is the second of those multiplied by the number of times a year it is genuinely billed — which is thirteen, not twelve, for anyone on a four-week cycle.
| Company & compound | Advertised | Walk-away | Year at this price | Visit |
|---|---|---|---|---|
| $99 | $99 | $1,188$99 × 12 | Visit | |
| $299 | $299 | $1,554.80$299 × 5.2 | Visit | |
| $99 | $198+$99 on the ad | $2,376$198 × 12 | Visit | |
| $199 | $199 | $2,388$199 × 12 | Visit | |
| $199 | $199 | $2,388$199 × 12 | Visit | |
| $199 | $199 | $2,388$199 × 12 | Visit | |
| $159 | $199+$40 on the ad | $2,388$199 × 12 | Visit | |
| $834 | $1,194+$360 on the ad | $2,388$1,194 × 2 | Visit | |
| $597 | $597 | $2,587$597 × 4.333333333333333 | Visit | |
| $249 | $249 | $2,988$249 × 12 | Visit | |
| $167 | $250+$83 on the ad | $3,000$250 × 12 | Visit | |
| $149 | $298+$149 on the ad | $3,576$298 × 12 | Visit | |
| $299 | $299 | $3,588$299 × 12 | Visit | |
| $179 | $299+$120 on the ad | $3,887$299 × 13 | Visit | |
| $258 | $448+$190 on the ad | $5,824$448 × 13 | Visit | |
| $89 | $89 | $1,068$89 × 12 | Visit | |
| $118 | $118 | $1,416$118 × 12 | Visit | |
| $135 | $135 | $1,620$135 × 12 | Visit | |
| $99 | $149+$50 on the ad | $1,788$149 × 12 | Visit | |
| $74 | $149+$75 on the ad | $1,788$149 × 12 | Visit | |
| $133 | $150+$17 on the ad | $1,800$150 × 12 | Visit | |
| $158 | $158 | $1,896$158 × 12 | Visit | |
| $67 | $149+$82 on the ad | $1,937$149 × 13 | Visit | |
| $149 | $154.95+$5.95 on the ad | $2,014.35$154.95 × 13 | Visit | |
| $138 | $178+$40 on the ad | $2,136$178 × 12 | Visit | |
| $159 | $179+$20 on the ad | $2,148$179 × 12 | Visit | |
| $119 | $179+$60 on the ad | $2,148$179 × 12 | Visit | |
| $199 | $199 | $2,388$199 × 12 | Visit | |
| $116 | $199+$83 on the ad | $2,388$199 × 12 | Visit | |
| $99 | $199+$100 on the ad | $2,388$199 × 12 | Visit | |
| $179 | $249+$70 on the ad | $2,988$249 × 12 | Visit | |
| $149 | $264.50+$115.50 on the ad | $3,174$264.50 × 12 | Visit | |
| $179 | $249+$70 on the ad | $3,237$249 × 13 | Visit | |
| $217 | $297+$80 on the ad | $3,564$297 × 12 | Visit | |
| $179 | $299+$120 on the ad | $3,588$299 × 12 | Visit | |
| $160 | $315+$155 on the ad | $3,780$315 × 12 | Visit | |
| $188 | $448+$260 on the ad | $5,376$448 × 12 | Visit | |
| $328 | $418.99+$90.99 on the ad | $5,446.87$418.99 × 13 | Visit | |
| $238 | $498+$260 on the ad | $5,976$498 × 12 | Visit | |
| $349 | $578+$229 on the ad | $6,936$578 × 12 | Visit |
Every price was read off the company's own page on the date shown beside it. The capture procedure, and the five ways a price gets captured wrong, are on our methodology page.
What this board leaves off, and why
17 priced rows in our reviews look like they could belong on this board and are deliberately not on it. Each is named here with the reason, because a ranking you cannot see the edges of is one you have to take on trust — and every one of these prices is published in full on the review it came from.
Alinwell — Compounded semaglutide injection
Alinwell's audience is verified women in its own words — it describes itself as "a telehealth weight-care practice for women" and sells "GLP-1 weight care for women". Its intake does offer Male at step five, which its review records as a contradiction; a form field is not the company's statement of who it serves, and the published copy is. Every Alinwell row is therefore off the men's board and on the women's.
Alinwell — Compounded tirzepatide injection
Alinwell's audience is verified women in its own words — it describes itself as "a telehealth weight-care practice for women" and sells "GLP-1 weight care for women". Its intake does offer Male at step five, which its review records as a contradiction; a form field is not the company's statement of who it serves, and the published copy is. Every Alinwell row is therefore off the men's board and on the women's.
Alinwell — GLP-1 microdose injection
Alinwell's audience is verified women in its own words — it describes itself as "a telehealth weight-care practice for women" and sells "GLP-1 weight care for women". Its intake does offer Male at step five, which its review records as a contradiction; a form field is not the company's statement of who it serves, and the published copy is. Every Alinwell row is therefore off the men's board and on the women's.
Alinwell — GLP-1 oral
Alinwell's audience is verified women in its own words — it describes itself as "a telehealth weight-care practice for women" and sells "GLP-1 weight care for women". Its intake does offer Male at step five, which its review records as a contradiction; a form field is not the company's statement of who it serves, and the published copy is. Every Alinwell row is therefore off the men's board and on the women's.
Alloy — Compounded semaglutide — weekly injection
Alloy's audience is verified women in its own words — its Wegovy page states the program is "recommended for pre-, peri- and post-menopausal women", and its clinicians are described as trained in treating women in perimenopause and menopause. Every Alloy row is therefore off the men's board and on the women's.
Alloy — Compounded tirzepatide — weekly injection
Alloy's audience is verified women in its own words — its Wegovy page states the program is "recommended for pre-, peri- and post-menopausal women", and its clinicians are described as trained in treating women in perimenopause and menopause. Every Alloy row is therefore off the men's board and on the women's.
Alloy — Compounded liraglutide — daily injection
Alloy's audience is verified women in its own words — its Wegovy page states the program is "recommended for pre-, peri- and post-menopausal women", and its clinicians are described as trained in treating women in perimenopause and menopause. Every Alloy row is therefore off the men's board and on the women's.
Alloy — Foundayo® — orforglipron, oral GLP-1 pill
Alloy's audience is verified women in its own words — its Wegovy page states the program is "recommended for pre-, peri- and post-menopausal women", and its clinicians are described as trained in treating women in perimenopause and menopause. Every Alloy row is therefore off the men's board and on the women's.
Alloy — Wegovy® pill — oral semaglutide
Alloy's audience is verified women in its own words — its Wegovy page states the program is "recommended for pre-, peri- and post-menopausal women", and its clinicians are described as trained in treating women in perimenopause and menopause. Every Alloy row is therefore off the men's board and on the women's.
Alloy — Wegovy® — semaglutide injection
Alloy's audience is verified women in its own words — its Wegovy page states the program is "recommended for pre-, peri- and post-menopausal women", and its clinicians are described as trained in treating women in perimenopause and menopause. Every Alloy row is therefore off the men's board and on the women's.
Alloy — Zepbound® — tirzepatide injection
Alloy's audience is verified women in its own words — its Wegovy page states the program is "recommended for pre-, peri- and post-menopausal women", and its clinicians are described as trained in treating women in perimenopause and menopause. Every Alloy row is therefore off the men's board and on the women's.
Alloy — Zepbound® KwikPen® — tirzepatide autoinjector
Alloy's audience is verified women in its own words — its Wegovy page states the program is "recommended for pre-, peri- and post-menopausal women", and its clinicians are described as trained in treating women in perimenopause and menopause. Every Alloy row is therefore off the men's board and on the women's.
Hers — Oral semaglutide — Wegovy Pill
Hers sells its weight-loss program to women and titles it so. The page these prices are read from carries the title "Weight Loss Care for Women, Built to Last | Hers", and the homepage is titled "Hers | Women's Healthcare, Online" with the description "Personalized healthcare for women." — read on 2026-08-09 out of the raw server HTML, not from the brand name. It publishes no statement refusing men, and it is not a clinical restriction; but its own site carries no men's program page at all, and listing it here would credit it with something it does not say.
Hers — Semaglutide — Wegovy Pen
The same company and the same published titles. Every Hers price, membership line included, is on its review.
Hers — Tirzepatide — Zepbound Vial
The same company and the same published titles. This row is ranked on the women's board and on our branded GLP-1 board.
Midi Health — Semaglutide — compounded
Midi says who it is for in a single sentence, in its own help center: "Midi is a virtual clinic that provides specialty care for women 35+." The banner over the page these prices are read from says the same thing about the weight program specifically — "Finally, hormone-first weight care built for women" — and the homepage title is "Meet Midi: Insurance-Covered Care from Women's Health Specialists", all read on 2026-08-09. Midi publishes no statement refusing men and this is not a clinical restriction; but its 1,245-URL sitemap carries no men's program page, and listing it here would credit it with something it does not claim.
Midi Health — Tirzepatide — compounded
The same company and the same published sentence. Both of Midi's GLP-1 prices, and the separate visit fee that never appears beside them, are on its review, and this row is ranked on the women's board.
Key terms
Show definitions
- Walk-away price
- What one cycle costs at the standing, no-commitment rate — what you pay if you stop after it. Not a prepay tier and not a first-month promotion.
- Year at this price
- The walk-away price multiplied by the number of times it is actually billed in a year: 12 on a calendar-month cycle, 13 on a four-week cycle.
- Advertised price
- The figure the company leads with on its own pricing page. It is shown here beside the price you pay rather than instead of it.
What this board does not tell you
Whether you qualify
Coverage varies by state, and several of these companies serve fewer states than they appear to. Each review names the exclusions its company actually discloses.
Whether the care is good
This board ranks on cost, not on care. We have not assessed anyone's clinical care, and there is no quality score anywhere on this site.
What your insurer pays
Every figure here is a cash price. What a covered drug costs you depends on your own plan's formulary and deductible, and no public source publishes a per-drug copay.
Whether the price will hold
Plans restructure without notice. Every row carries the date it was read so you can see how old the number is before you rely on it.
Frequently asked questions
Why is this board shorter than the main GLP-1 ranking?
Because it is a different question, and for a long time it was not. Until each review recorded who a company says it serves, the only rule available was "does not restrict to women", which qualified almost every seller — so this board carried exactly the same rows as our main GLP-1 board under a different heading. That was thin content and we have said so rather than quietly leaving it. Now a company is here because its own pages say it treats men, and the sellers that publish nothing on the point are on neither this board nor the women's one.
Does this board make any claim about how GLP-1s affect men?
No. Nothing on this site makes a claim about how a medicine behaves in one sex versus another. This board ranks companies on what they charge over a year and reports who they say they treat — it is a statement about pricing pages, not about bodies.
Do the men's-health brands here cost more?
One is among the dearest rows on this board and the other is among the cheaper ones, so there is no pattern to report. Both are ranked by the same arithmetic as every other row, at the figure they charge, and their reviews carry the rest of their catalogs.
Why does this board name five excluded rows and the women's board name three?
Because the counts are just how many priced GLP-1 rows the excluded companies happen to publish, not a judgment about either sex. Two women's-facing sellers are named here — one with three priced rows and one with two — while the women's board names two men's-facing sellers whose rows come to three between them. What is symmetric is the rule: each board names every company whose audience we established and then deliberately left off, with the sentence that decided it, and neither board names the companies nobody has established an audience for, because that is one uniform reason stated once above rather than sixty identical entries.
Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.